Table of contents


On 25 July 2006, orphan designation (EU/3/06/384) was granted by the European Commission to Pharmexa A/S, Denmark, for human telomerase reverse transcriptase peptide (611-626) for the treatment of pancreatic cancer.

The sponsorship was transferred to Gemvax A/S, Norway, in May 2009.

The sponsor’s address was updated in April 2020.

The sponsorship was transferred to Klifo A/S, Denmark, in May  2020.

Key facts

Active substance
Human telomerase reverse transcriptase peptide (611-626)
Disease / condition
Treatment of pancreatic cancer
Date of first decision
EU designation number

Sponsor's contact details

Klifo A/S
Smedeland 36
2600 Glostrup Hovedstaden

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating